Targeting MPO expression or enzyme activity sensitizes AML cells to cytarabine therapy by triggering oxidative damage and persistent oxidative stress, especially in AML cells with high MPO expression43 (Figure S4B). This evidence concerns the gene MPO and acute myeloid leukemia.